BOSTON, April 20 (Reuters) - A sixth patient taking Biogen Idec Inc’s multiple sclerosis drug Tysabri has developed a potentially deadly brain infection since the drug was reintroduced onto the market in July 2006.
BOSTON, April 20 (Reuters) - A sixth patient taking Biogen Idec Inc’s multiple sclerosis drug Tysabri has developed a potentially deadly brain infection since the drug was reintroduced onto the market in July 2006.
